06 May 2013, BioSpectrum Bureau , BioSpectrum
Singapore: Oramed Pharmaceuticals' article titled, ‘Glucose-reducing effect of the ORMD-0801 oral insulin preparation in patients with uncontrolled type 1 diabetes : A pilot study', has been published in Plos One, an international, peer-reviewed, open-access journal that covers primary scientific and medical research.
The article details the results of a clinical study, in which ORMD-0801 was administered to patients with unstable type 1 diabetes, in conjunction with their regular anti-diabetes treatment regimens.
These patients typically suffer from unpredictable and frequent swings in their blood sugar levels, which often demand hospitalization and severely disrupt their quality of life.
The addition of ORMD-0801 was well tolerated and significantly stabilized blood sugar levels in this patient group. A significant drop in the frequency of above-normal blood sugar readings was observed, as well as a decrease in overall blood sugar levels throughout the day.
Dr Nadav Kidron, CEO, Oramed, said that, "These published results lay the groundwork for further study of the potential of ORMD-0810 as a treatment that can considerably aid a patient population resistant to standard anti-diabetes treatment protocols.".